You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
SBC: A&G PHARMACEUTICAL, INC. Topic: 102Cost-effective and minimally invasive monitoring of metastatic breast cancer (MBC) patients for disease progression or response to therapy is an unmet need in the clinical management of the disease. Imaging technologies are currently the gold standard of such monitoring. However, there is controversy regarding the type and frequency of imaging required. Imaging is expensive, time consuming, slow t ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 103Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2
SBC: ENCODIA INC Topic: 100ABSTRACT The goal of this proposal is to repurpose technology developed for Next-Gen Proteomics to develop a highly-scalable digital serotyping technology for infectious disease analysis, with particular application to influenza and Covid-19. The approach is broadly applicable and should greatly improve upon cost, sensitivity, usability, and throughput of population-level serotyping and greatly im ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Validation of a salivary miRNA diagnostic test for autism spectrum disorder
SBC: Quadrant Biosciences Inc. Topic: 103Autism spectrum disorder (ASD) is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction, as well as restrictive, repetitive interests and behaviors. ASD is an increasing public health concern, with about 1 in 45 American children diagnosed with ASD in 2014, a 10-fold increase in prevalence over the past 40 years. The effect of ASD on both ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
SBC: A&G PHARMACEUTICAL, INC. Topic: 102Innew cases of breast cancerBCandrelated deaths are expected in the USof these are patients with aggressive triple negative BCTNBCor anti estrogen aromatase inhibitor resistantAE AIBC that do not have targeted therapy and rely on radiotherapy and aggressive chemotherapyA new approach that benefits these patients and provides increased life expectancy needs to be developedWe have identified GPa gly ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
TB Diagnostics at the Point of Care
SBC: AKONNI BIOSYSTEMS INC Topic: NIAIDABSTRACT Tuberculosis ranks in the top ten worldwide cause of death and now ranks ahead of HIV, making it the number one infectious disease killer. Perhaps, most alarming is the global prevalence of multidrug-resistant TB (MDR- TB) and extensively drug-resistant TB (XDR-TB): more than 5% of new TB cases are MDR-TB and 10% of these have XDR-TB. And, the number of enrolled XDR-TB cases has grown fro ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of an Ultrasound-guided Vascular Access Device
SBC: PERCEPTIVE NAVIGATION LLC Topic: NHLBIPROJECT SUMMARY Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular and cardiothoracic diseases. An interventional catheter with forward-viewing ultrasound imaging capability will be developed to enable image-guided access to blood vessels and internal organs. Phase 1 and 2 experiments demonstrate feasibility of building a high res ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical Data Intelligence & Advanced Analytics to Reduce Drug Diversion across the Care Delivery Cycle and Drug Supply Chain in Health Systems
SBC: Invistics Corporation Topic: NIDAThis SBIR project will research mechanisms to detect when Health Care WorkersHCWsin hospitals steal ordivertlegal drugs either to abuse themselves or to illegally sell to othersWe focus on HCWs in hospitals because of the alarming rates of substance abuse and diversion in hospitalswith multiple studies finding roughlyof our nation s nursesanesthesiologistsand pharmacists are currently diverting dr ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Painless Defibrillation
SBC: Coridea, LLC Topic: NHLBIProject SummaryThe purpose of the proposed work is first-in-man testing of novel painless defibrillation (PaDe) therapy. Sudden cardiac arrest (SCA) remains the number one killer in western civilization. The underlying mechanism of SCA is usually ventricular fibrillation (VF), and survival depends on prompt defibrillation. Existing defibrillators rely on the delivery of a brief high voltage shock ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health